Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide

Drugs and Aging

Volumn 11, Issue 2, 1997, Pages 119-131

  Goldberg, Richard J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MOCLOBEMIDE; NEFAZODONE; NORADRENALIN; SEROTONIN; VENLAFAXINE;

AGED; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; GERONTOPSYCHIATRY; HUMAN; MELANCHOLIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0030758127     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711020-00004     Document Type: Review

References (86)

1. National Institute of Health Consensus Development Conference. Bethesda (MD): US Department of Health and Human Services, 1991: 1-6
2. American Psychiatry Association. Diagnostic and statistical manual of mental disorders. 3rd. ed, rev. Washington, DC: American Psychiatric Association, 1987
3. Depression Guideline Panel. Depression in primary care. In: Detection and diagnosis: clinical practice guideline. Vol. 1. AHCPR Publication No. 93-0550. Rockville (MD): US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993: 55-65
4. Salzman C. Pharmacological treatment of depression in elderly patients. In: Schneider LS, Reynolds III CF, Lebowitz BD, et al., editors. Diagnosis and treatment of depression in late life. Washington, DC: American Psychiatric Press, 1994: 181-244
5. Schneider LS, Reynolds III CF, Lebowitz BD, et al., editors. Diagnosis and treatment of depression in late life: results of the NIH Consensus Development Conference. Washington, DC: American Psychiatric Press, 1994
6. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990; 51 Suppl.: 41-7
7. Lazarus LW, Groves L, Gierl B, et al. Efficacy of phenelzine in geriatric depression. Biol Psychiatry 1986; 21: 699-701
8. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOI vs TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155-6
9. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of depressed elderly patients. Arch Gen Psychiatry 1989; 46: 783-6
10. Hindmarch I. A review of the psychomotor effects of paroxetine. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 65-7
11. Schneider L. Pharmacologic considerations in the treatment of late-life depression. Am J Geriatr Psychiatry 1996; 4 Suppl. 1:S51-65
12. Feighner J, Boyer W, Meredith WC. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988; 153 Suppl.: 105-8
13. Salzman C, Schneider L, Lebowitz B. Antidepressant treatment of very old patients. Am J Geriatr Psychiatry 1993; 1 (1): 21-9
14. Orengo CA, Kunik ME, Molinari V, et al. The use and tolerability of fluoxetine in geropsychiatric inpatients. J Clin Psychiatry 1996; 57: 12-6
15. Tollefson G, Holman S. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 1993; 8: 253-9
16. Roose SP, Classman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735-9
17. Goldberg RJ. The P-450 system: definition and relevance to the use of antidepressants in medical practice. Arch Fam Med 1996; 5: 406-12
18. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151: 1069-72
19. Aguglia E, Casacchia M, Cassano GB, et al. Double blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8(3): 197-202
20. Rudorfer M, Manji H, Potter W. Comparative tolerability profiles of the newer versus older antidepressants. Drug Sat 1994; 10: 18-46
21. Brymer C, Winograd C. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992; 40: 902-5
22. Baldwin D, Fineberg N, Montgomery S. Fluoxetine. fluvoxamine, and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991; 6: 491-3
23. Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211-3
24. Cohen B, Mahelsky M, Adler L. More cases of SIADH with fluoxetine. Am J Psychiatry 1990; 147: 948-9
25. Pollock B, Perel J, Reynolds CI. Pharmacodynamic issues relevant to geriatric psychopharmacology. J Geriatr Psychiatry Neurol 1990; 3: 221-8
26. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant profile of the novel bicyclic compound, Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35: 4493-7
27. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-9
28. Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-24
29. Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56: 14-21
30. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant, Ann Pharmacother 1995; 29: 387-95
31. Montgomery S. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993; 54: 119-26
32. Troy SM, Lucki I, Peirgies AA, et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995; 35: 410-9
33. Ball S, Ahern D, Kao J, et al. Venlafaxine (VF): effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation: comparative studies with fluoxetine (flu) and effects on CYP1A2, CYP2A4, and CYP2C9. Clin Pharmacol Ther 1996; 59: 170
34. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55 (9 Suppl. A): 62-8
35. Rudolph R, Derivan AT. The safely and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996; 16 Suppl. 2: 54S-9S
36. Grunder G, Wetzel H, Schlosser R, et al. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure: assessment by automatic 24 hour monitoring. Pharmacopsychiatry 1996; 29: 72-8
37. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55 Suppl. A: 62-8; discussion 69-70, 98-100
38. Data on file, Wyeth-Ayerst Laboratories
39. Guelfi JD, While C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995; 56: 450-8
40. Clerc GE, Ruiny P, Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139-43
41. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994; 14: 419-23
42. Khan A, Rudolph R, Baumel B, et al. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharm Bull 1995; 31: 753-8
43. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-5
44. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995; 56 Suppl. 6: 3-11
45. Data on file, Bristol-Myers Squibb
46. Food and Drug Administration. Psychopharmacology Drugs Advisory Committee Meeting. Serzone (nefazodone HCl): safety and effectiveness in use as an antidepressant. Rockville (MD): Food and Drug Administration, 1993 Jul 19
47. Hamik A, Peroutka S. I-(M-chlorophenyl)piperazine(m-CPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989; 25: 569-75
48. Mayol RF, Cole CA, Luke CM, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-11
49. Food and Drug Administration (FDA). Serzone (nefazodone HCl): safety and effectiveness in use as an antidepressant. Psychopharmacologic Drugs Advisory Committee Meeting. Rockville (MD): FDA, 1993
50. Barbhaiya R, Buch A, Greene D, A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996; 16: 19-25
51. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1495; 56 Suppl. 6: 30-6
52. Frewer L, Lader M. The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects. Int Clin Psychopharmacol 1993; 8: 13-20
53. FDA committee discussion of nefazodone. Scrip 1993; 1842: 20-1
54. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine. nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 Suppl. 6: 12-21
55. Gelenberg AJ, editor. Biological therapies in psychiatry, Vol. 19 no, 5. 1996 May: 17
56. Fontaine R, Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 1993; 16 Suppl. 3; S45-50
57. Gammans R, Breul H, Roberts D, et al. Cardiovascular effects of nefazodone and imipramine in elderly volunteers. Clin Neuropharmacol 1992; Suppl. 1, Part B: 332B
58. Armitage R, Rush AJ, Trivedi M, et al. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994; 10: 123-7
59. Sharply A, Walsh A, Cowen P, Nefazodone - a novel antidepressant - may increase REM sleep. Biol Psychiatry 1992; 31: 1070-3
60. Balon R, Yeragani VK, Pohl R, et al. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993; 54: 209-12
61. Harrison WM, Rabkin JG, Ehrharot AA, et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986; 6: 144-9
62. Data on file, Bristol-Myers Squibb
63. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo controlled trial. Br J Psychiatry 1994; 164: 802-5
64. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234-41
65. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone. imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996; 57 Suppl. 2: 15-8
66. Marcus R, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996; 57 Suppl. 2: 19-23
67. Krishnan KRR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Association Press. 1995: 183-93
68. Nair NP, Ahmed SK, Kin NM, et al. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand Suppl 1995; 386: 28-35
69. Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver and kidney function. Acta Psychiatr Scand Suppl 1990; 360: 94-7
70. Tiller J, Maguire K, Davies B, Tyramine pressure response with moclobemide, a reversible monoamine oxidase inhibitor. Psychiatry Res 1987; 22: 213-20
71. Korn A, Gasic S, Jung M, et al. Influence of moclobemide (Ro 11-1163) on the peripheral adrenergic system: interaction with tyramine and tricyclic antidepressants. In: Tipton KF, Dostert P, Benedetti M, editors. Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. London: Academic Press. 1984: 487-96
72. Zimmer R, Gieschke R, Fischbach R, et al. Interaction studies with moclobemide. Acta Psychiatr Scand Suppl 1990; 360: 84-6
73. Fitton A, Faulds D, Goa K. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561-96
74. Blois R, Gaillard JM. Effects of moclobemide on sleep in healthy human subjects. Acta Psychiatr Scand Suppl 1990; 360: 73-5
75. Monti J, Alterwain P, Monti D. The effect of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 1990; 20: 201-8
76. Hoff P, Colling G, Kapfhammer HP, et al. Cimoxatone and moclobemide, two new MAO inhibitors: influence in sleep parameters in patients with major depressive disorder. Pharmacopsychiatry 1986; 19; 249-50
77. Radies J. Efficacy of moclobemide therapy in depressed patients above 65 [abstract]. Eur Neuropsychopharmacol 1995; 5 Spec. Iss.: 298
78. Altamura A, Aguglia E. Moclobemide vs fluoxetine in elderly outpatients with major depression or dysthymia: a double-blind trial (abstract). Eur Psychiatry 1994; 9 Suppl. 1; 163S
79. Bugarski-Kirola D, Zivkovic D, Stankovic Z. Fluoxetine versus moclobemide in elderly depressed patients [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 1: 20
80. Bocksberger J-P, Gachoud JP, Richard J, et al. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1994; 9 Suppl. 1: 99S
81. Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995; 33: 1-9
82. De Vanna M, Kummer J, Agnoli A, et al. Moclobemide compared with second-generation antidepressants in elderly people. Acta Psychiatr Scand Suppl 1990; 360: 64-6
83. Tiller J, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. Int J Geriatr Psychiatry 1990; 5: 199-204
84. Barak Y, Suholitsky H, Noy S. Moclobemide treatment of resistant depression in a patient with vascular dementia. Hum Psychopharmacol 1996; 11: 67-8
85. Roth M, Mountjoy CQ, Amrein R, et al. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996; 168: 149-57
86. Georgotas A, McCue R. The additional benefit of extending an antidepressant trial past seven weeks in the depressed elderly. Int J Geriatr Psychiatry 1989; 4: 191-5